WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on…
Pharmaceutical Veteran to Help Propel Manufacturing Scale-Up as Clinical-Stage Biotech Prepares to Enter Phase 2 Clinical TrialsNEW HAVEN, Conn., April…
Enable Cloud Platform trained on high plex spatial imaging datasets across 20,000 samples run on the PhenoCycler® SystemCommercial launch at…
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin…
Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancersFOSTER CITY, Calif.,…
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated PipelineWILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD),…
MINNEAPOLIS, April 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics…
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy…
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented;…
The Company’s eIF4A inhibitor, zotatifin, will be tested in specific genomically-defined subgroups, including standard risk patients as well as high-risk…